Abstract
Enzalutamide (Xtandi—Astellas, Medivation), an androgen receptor inhibitor previously known as MDV3100, has been approved for men with late-stage (metastatic) castration-resistant prostate cancer previously treated with docetaxel. The drug was reviewed under FDA's priority review program and received approval 3 months ahead of schedule.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
